Anja Weinreich Olsen

Anja Weinreich Olsen

Auto-generated profile, based on publicly available information

Anja Weinreich Olsen

Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AOAnja Weinreich Olsen
Anja Weinreich Olsen
MTMichael Theisen
Michael Theisen
DCDennis Christensen
Dennis Christensen
FFFrank Follmann
Frank Follmann
PAPeter Andersen
Peter Andersen
The chlamydial proteins CT443 (OmcB) and CT521 (rl16) have previously been identified as human B and/or T cell targets during a chlamydial infection in humans. Here we compare the protective effector mechanism promoted by a fusion protein composed of CT521 and CT443 (CTH1) with a primary intranasal Chlamydia muridarum infection known to provide high levels of protection against a genital chlamydial challenge. The fusion protein CTH1, adjuvanted with a strong Th1 inducing cationic adjuvant (CAF01), significantly reduced the bacterial shedding compared to a control group in both a C. trachomatis Serovar D and C. muridarum challenge model. The CTH1/CAF01 vaccine was found to induce polyfunctional T cells consisting of TNFα/IL-2 and TNFα/IL-2/IFN-γ positive cells and high titers of CTH1 specific IgG2a and IgG1. By depletion experiments the protection in the C. muridarum challenge model was demonstrated to be mediated solely by CD4+ T cells. In comparison, an intranasal infection with C. muridarum induced a T cell response that consisted predominantly of TNFα/IFN-γ co-expressing effector CD4+ T cells and an antibody response consisting of C. muridarum specific IgG1, IgG2a but also IgA. This response was associated with a high level of protection against challenge—a protection that was only partially dependent on CD4+ T cells. Furthermore, whereas the antibody response induced by intranasal infection was strongly reactive against the native antigens displayed in the chlamydial elementary body, only low levels of antibodies against this preparation were found after CTH1/CAF01 immunization. Our data demonstrate that CTH1 vaccination promotes a CD4+ T cell dependent protective response but compared with intranasal C. muridarum infection lacks a CD4 independent protective mechanism for complete protection.

23 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AOAnja W. Olsen
Anja W. Olsen
IRIda Rosenkrands
Ida Rosenkrands
CJChristina S. Jacobsen
Christina S. Jacobsen
HCHannah M Cheeseman
Hannah M Cheeseman
MKMax P. Kristiansen
Max P. Kristiansen
FFFrank Follmann
Frank Follmann
The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here, we report a comparative immunological characterization of CTH522/CAF®01 in female mice and humans. We find a range of immune signatures that translate from mouse to human, including a Th1/Th17 cytokine profile and antibody functionality. We identify vaccine-induced T cell epitopes, conserved among Chlamydia serovars, and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice, and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study.

19 April 2021 in npj Vaccines
Verified
Journal Article
Open access
PDF file
AOAnja Weinreich Olsen
Anja Weinreich Olsen
IRIda Rosenkrands
Ida Rosenkrands
Martin HollandMartin Holland
Martin Holland
PAPeter Andersen
Peter Andersen
FFFrank Follmann
Frank Follmann
Ocular and urogenital infections withChlamydia trachomatis (C.t.) are caused by a range of different serovars. The firstC.t. vaccine in clinical development (CTH522/CAF®01) induced neutralizing antibodies directed to the variable domain 4 (VD4) region of major outer membrane protein (MOMP), covering predominantly B and intermediate groups of serovars. The VD1 region of MOMP contains neutralizing B-cell epitopes targeting serovars of the C and C-related complex. Using an immuno-repeat strategy, we extended the VD1 region of SvA and SvJ to include surrounding conserved segments, extVD1Aand extVD1J, and repeated this region four times. The extVD1A*4 was most immunogenic with broad cross-surface and neutralizing reactivity against representative members of the C and C-related complex serovars. Importantly, in vitro results for extVD1A*4 translated into in vivo biological effects, demonstrated by in vivo neutralization of SvA and protection/cross-protection against intravaginal challenge with both SvA and the heterologous SvIa strain.

1 November 2006 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AOAnja Weinreich Olsen
Anja Weinreich Olsen
FFFrank Follmann
Frank Follmann
KJKlaus Jensen
Klaus Jensen
PHPeter Hojrup
Peter Hojrup
RLRobert Leah
Robert Leah
MTMichael Theisen
Michael Theisen
BackgroundThe human immune response to a Chlamydia trachomatis serovar D lysate was investigated in patients with urogenital C. trachomatis infection


10 September 2016 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
KEKarin Erneholm
Karin Erneholm
ELEmma Lorenzen
Emma Lorenzen
SBSarah Bøje
Sarah Bøje
AOAnja Weinreich Olsen
Anja Weinreich Olsen
PAPeter Andersen
Peter Andersen
JAJørgen Agerholm
Jørgen Agerholm
Chlamydia is one of the most common sexually transmitted diseases in humans worldwide, causing chronic lesions in the reproductive tract. Due to its often asymptomatic course, there is limited knowledge about the initial changes in the genital tract following infection. This study employs a novel sexually mature minipig model to investigate the initial histopathological changes following vaginal infection with Chlamydia trachomatis serovar D. A vaginal inoculation resulted in an infection primarily affecting the lower genital tract. The histopathological changes were characterized by a subepithelial inflammation consisting of neutrophils and mononuclear cells, followed by an increase in the number of plasma cells within the sub-epithelial stroma of the vagina. Detection of Chlamydia was associated with expression of cyclooxygenase-2 and interleukin-8 by superficial epithelial cells. The infection was self-limiting, with a duration of 7 days. Neutrophils, plasma cells and IL-8 have been linked with Chlamydia genital infection of unknown duration in human patients. In this study, we observe a similar pattern of local immune response/inflammation following experimental inoculation suggesting this porcine model shows promise as a model for translational chlamydia research.